1
|
Quiralte M, Barquín A, Yagüe-Fernández M, Navarro P, Grazioso TP, Sevillano-Fernández E, Rodriguez-Moreno JF, Balarezo-Saldivar A, Peinado H, Izquierdo E, Millán C, López-Carrasco I, Prieto M, Madurga R, Fernández-Miranda I, Ruiz-Llorente S, García-Donas J. Proteomic profiles of peritoneal fluid-derived small extracellular vesicles correlate with patient outcome in ovarian cancer. J Clin Invest 2024; 134:e176161. [PMID: 38564289 DOI: 10.1172/jci176161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2023] [Accepted: 03/21/2024] [Indexed: 04/04/2024] Open
Abstract
Cancer-derived small extracellular vesicles (sEVs) are capable of modifying the tumor microenvironment and promoting tumor progression. Ovarian cancer (OvCa) is a lethal malignancy that preferentially spreads through the abdominal cavity. Thus, the secretion of such vesicles into the peritoneal fluid could be a determinant factor in the dissemination and behavior of this disease. We designed a prospective observational study to assess the impact of peritoneal fluid-derived sEVs (PFD-sEVs) in OvCa clinical outcome. For this purpose, 2 patient cohorts were enrolled: patients with OvCa who underwent a diagnostic or cytoreductive surgery and nononcological patients, who underwent abdominal surgery for benign gynecological conditions and acted as the control group. Systematic extraction of PFD-sEVs from surgical samples enabled us to observe significant quantitative and qualitative differences associated with cancer diagnosis, disease stage, and platinum chemosensitivity. Proteomic profiling of PFD-sEVs led to the identification of molecular pathways and proteins of interest and to the biological validation of S100A4 and STX5. In addition, unsupervised analysis of PFD-sEV proteomic profiles in high-grade serous ovarian carcinomas (HGSOCs) revealed 2 clusters with different outcomes in terms of overall survival. In conclusion, comprehensive characterization of PFD-sEV content provided a prognostic value with potential implications in HGSOC clinical management.
Collapse
Affiliation(s)
- Miguel Quiralte
- Laboratory of Innovation in Oncology, Clara Campal Comprehensive Cancer Centre (HM CIOCC), HM Sanchinarro University Hospital, Madrid, Spain
- Institute of Applied Molecular Medicine, Faculty of Medicine, Universidad San Pablo-CEU, Alcorcón, Madrid, Spain
| | - Arantzazu Barquín
- Laboratory of Innovation in Oncology, Clara Campal Comprehensive Cancer Centre (HM CIOCC), HM Sanchinarro University Hospital, Madrid, Spain
- HM CIOCC, HM Sanchinarro University Hospital, Madrid, Spain
| | - Mónica Yagüe-Fernández
- Laboratory of Innovation in Oncology, Clara Campal Comprehensive Cancer Centre (HM CIOCC), HM Sanchinarro University Hospital, Madrid, Spain
| | - Paloma Navarro
- Laboratory of Innovation in Oncology, Clara Campal Comprehensive Cancer Centre (HM CIOCC), HM Sanchinarro University Hospital, Madrid, Spain
- Institute of Applied Molecular Medicine, Faculty of Medicine, Universidad San Pablo-CEU, Alcorcón, Madrid, Spain
| | - Tatiana P Grazioso
- Laboratory of Innovation in Oncology, Clara Campal Comprehensive Cancer Centre (HM CIOCC), HM Sanchinarro University Hospital, Madrid, Spain
| | - Elena Sevillano-Fernández
- Laboratory of Innovation in Oncology, Clara Campal Comprehensive Cancer Centre (HM CIOCC), HM Sanchinarro University Hospital, Madrid, Spain
- HM CIOCC, HM Sanchinarro University Hospital, Madrid, Spain
| | - Juan F Rodriguez-Moreno
- Laboratory of Innovation in Oncology, Clara Campal Comprehensive Cancer Centre (HM CIOCC), HM Sanchinarro University Hospital, Madrid, Spain
- HM CIOCC, HM Sanchinarro University Hospital, Madrid, Spain
| | - Alejandra Balarezo-Saldivar
- Laboratory of Innovation in Oncology, Clara Campal Comprehensive Cancer Centre (HM CIOCC), HM Sanchinarro University Hospital, Madrid, Spain
- Institute of Applied Molecular Medicine, Faculty of Medicine, Universidad San Pablo-CEU, Alcorcón, Madrid, Spain
| | - Héctor Peinado
- Microenvironment and Metastasis Laboratory, Molecular Oncology Program, Spanish National Cancer Research Centre, Madrid, Spain
| | - Elena Izquierdo
- Institute of Applied Molecular Medicine, Faculty of Medicine, Universidad San Pablo-CEU, Alcorcón, Madrid, Spain
| | - Carlos Millán
- Gynecologic Unit, HM Montepríncipe University Hospital, Boadilla del Monte, Madrid, Spain
| | - Irene López-Carrasco
- Gynecologic Unit, HM Montepríncipe University Hospital, Boadilla del Monte, Madrid, Spain
| | - Mario Prieto
- Department of Pathological Anatomy, Therapeutic Targets Laboratory, HM Sanchinarro University Hospital, Madrid, Spain
| | - Rodrigo Madurga
- Faculty of Experimental Sciences, Francisco de Vitoria University, Pozuelo de Alarcón, Madrid, Spain
| | - Ismael Fernández-Miranda
- R&D Oncology Business Unit, Pharmacogenomic and Cell Biology Departments, PharmaMar, Colmenar Viejo, Madrid, Spain
| | - Sergio Ruiz-Llorente
- Laboratory of Innovation in Oncology, Clara Campal Comprehensive Cancer Centre (HM CIOCC), HM Sanchinarro University Hospital, Madrid, Spain
- Department of Biomedicine and Biotechnology, Genetics Area, Universidad de Alcalá, Alcalá de Henares, Madrid, Spain
| | - Jesús García-Donas
- Laboratory of Innovation in Oncology, Clara Campal Comprehensive Cancer Centre (HM CIOCC), HM Sanchinarro University Hospital, Madrid, Spain
- Institute of Applied Molecular Medicine, Faculty of Medicine, Universidad San Pablo-CEU, Alcorcón, Madrid, Spain
- HM CIOCC, HM Sanchinarro University Hospital, Madrid, Spain
| |
Collapse
|
2
|
García-Donas J, de Velasco G, Madurga R, Chamorro J, Rosero D, Etxaniz O, Pérez-Gracia JL, Pinto Á, Cacho D, Barba M, Borrega P, Lázaro M, Rodriguez L, Villalobos L, García L, Cuellar A, Solís-Hernández MP, González A, Pernaut C, Rodríguez-Moreno JF. Case-control study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study. Clin Transl Oncol 2024; 26:732-738. [PMID: 37556096 DOI: 10.1007/s12094-023-03295-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2023] [Accepted: 07/24/2023] [Indexed: 08/10/2023]
Abstract
BACKGROUND Cancer is a risk factor for developing severe COVID19. Additionally, SARS-CoV2 has a special tropism for renal cells and complications like thrombosis or cytokine storm could be enhanced by standard treatments in kidney cancer (i.e., antiangiogenics or immunotherapy). Thus, understanding the impact of COVID19 in patients with this tumor is key for their correct management. METHODS We designed a retrospective case-control study comparing the outcome of three groups of advanced kidney cancer patients on systemic treatment: cohort A (developed COVID19 while on antiangiogenics), cohort B (developed COVID19 while on immunotherapy) and cohort C (non-infected). Matching factors were age, gender, and treatment. RESULTS 95 patients were recruited in 16 centers in Spain from September 2020 to May 2021. Finally, 85 were deemed as eligible (23 cohort A, 21 cohort B, 41 cohort C). Patients with COVID required more dose interruptions (25 vs. six) and hospitalizations (10 vs. none) than those without COVID (both p = 0.001). No difference between cohorts A and B was observed regarding hospitalization or length of stay. No ICU admission was registered and one patient in cohort B died due to COVID19. Regarding cancer evolution, three patients in cohort A presented progressive disease after COVID19 compared to two in cohort B. One case in cohort B, initially deemed as stable disease, achieved a partial response after COVID19. CONCLUSIONS Kidney cancer patients who developed COVID19 while on systemic therapy required more treatment interruptions and hospitalizations than those non-infected. However, no significant impact on cancer outcome was observed. Also, no difference was seen between cases on antiangiogenics or immunotherapy.
Collapse
Affiliation(s)
| | | | - Rodrigo Madurga
- Faculty of Experimental Sciences, Universidad Francisco de Vitoria, Madrid, Spain
| | | | - Diana Rosero
- Hospital Universitario Ramón y Cajal, Madrid, Spain
| | | | | | | | - Diego Cacho
- Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - María Barba
- HM Hospitales-Centro Integral Oncológico Clara Campal, Madrid, Spain
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Garcia-Donas J, Martínez-Urbistondo D, Velázquez Kennedy K, Villares P, Barquin A, Dominguez A, Rodriguez-Moreno JF, Caro E, Suarez del Villar R, Nistal-Villan E, Yagüe M, Ortiz M, Barba M, Ruiz-Llorente S, Quiralte M, Zanin M, Rodríguez C, Navarro P, Berraondo P, Madurga R. Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution. Front Immunol 2023; 14:1156603. [PMID: 37143685 PMCID: PMC10151807 DOI: 10.3389/fimmu.2023.1156603] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2023] [Accepted: 03/27/2023] [Indexed: 05/06/2023] Open
Abstract
Background Managing the inflammatory response to SARS-Cov-2 could prevent respiratory insufficiency. Cytokine profiles could identify cases at risk of severe disease. Methods We designed a randomized phase II clinical trial to determine whether the combination of ruxolitinib (5 mg twice a day for 7 days followed by 10 mg BID for 7 days) plus simvastatin (40 mg once a day for 14 days), could reduce the incidence of respiratory insufficiency in COVID-19. 48 cytokines were correlated with clinical outcome. Participants Patients admitted due to COVID-19 infection with mild disease. Results Up to 92 were included. Mean age was 64 ± 17, and 28 (30%) were female. 11 (22%) patients in the control arm and 6 (12%) in the experimental arm reached an OSCI grade of 5 or higher (p = 0.29). Unsupervised analysis of cytokines detected two clusters (CL-1 and CL-2). CL-1 presented a higher risk of clinical deterioration vs CL-2 (13 [33%] vs 2 [6%] cases, p = 0.009) and death (5 [11%] vs 0 cases, p = 0.059). Supervised Machine Learning (ML) analysis led to a model that predicted patient deterioration 48h before occurrence with a 85% accuracy. Conclusions Ruxolitinib plus simvastatin did not impact the outcome of COVID-19. Cytokine profiling identified patients at risk of severe COVID-19 and predicted clinical deterioration. Trial registration https://clinicaltrials.gov/, identifier NCT04348695.
Collapse
Affiliation(s)
- Jesus Garcia-Donas
- Gynecological, Genitourinary and Skin Cancer Unit HM CIOCC MADRID (Centro Integral Oncológico Clara Campal), Department of Basic Medical Sciences, Hospital Universitario HM Sanchinarro, HM Hospitales, Institute of Applied Molecular Medicine (IMMA), Facultad de Medicina, Universidad San Pablo CEU, CEU Universities, Madrid, Spain
- *Correspondence: Jesus Garcia-Donas, ;
| | | | | | - Paula Villares
- Internal Medicine Service Hospital HM Sanchinarro, Madrid, Spain
| | - Arántzazu Barquin
- Gynecological, Genitourinary and Skin Cancer Unit HM CIOCC MADRID (Centro Integral Oncológico Clara Campal), Department of Basic Medical Sciences, Hospital Universitario HM Sanchinarro, HM Hospitales, Institute of Applied Molecular Medicine (IMMA), Facultad de Medicina, Universidad San Pablo CEU, CEU Universities, Madrid, Spain
| | - Andrea Dominguez
- Internal Medicine Service Hospital HM Sanchinarro, Madrid, Spain
| | - Juan Francisco Rodriguez-Moreno
- Gynecological, Genitourinary and Skin Cancer Unit HM CIOCC MADRID (Centro Integral Oncológico Clara Campal), Department of Basic Medical Sciences, Hospital Universitario HM Sanchinarro, HM Hospitales, Institute of Applied Molecular Medicine (IMMA), Facultad de Medicina, Universidad San Pablo CEU, CEU Universities, Madrid, Spain
| | - Elena Caro
- Internal Medicine Service Hospital HM Sanchinarro, Madrid, Spain
| | | | - Estanislao Nistal-Villan
- Microbiology Section, Dpto. CC, Farmacéuticas y de la Salud, Facultad de Farmacia, Universidad San Pablo-CEU, Madrid, Spain
- Facultad de Medicina, Instituto de Medicina Molecular Aplicada (IMMA), Universidad San Pablo-CEU, Madrid, Spain
| | - Monica Yagüe
- Laboratory of Innovation in Oncology HM CIOCC MADRID (Centro Integral Oncológico Clara Campal), Department of Basic Medical Sciences, Facultad de Medicina, Hospital Universitario HM Sanchinarro, HM Hospitales, Institute of Applied Molecular Medicine (IMMA), Universidad San Pablo CEU, CEU Universities, Madrid, Spain
| | - Maria Ortiz
- Clinical Trials Pharmacy, Clara Campal Comprehensive Cancer Center, Hospital Universitario de Sanchinarro, Madrid, Spain
| | - Maria Barba
- Laboratory of Innovation in Oncology HM CIOCC MADRID (Centro Integral Oncológico Clara Campal), Department of Basic Medical Sciences, Facultad de Medicina, Hospital Universitario HM Sanchinarro, HM Hospitales, Institute of Applied Molecular Medicine (IMMA), Universidad San Pablo CEU, CEU Universities, Madrid, Spain
| | - Sergio Ruiz-Llorente
- Laboratory of Innovation in Oncology HM CIOCC MADRID (Centro Integral Oncológico Clara Campal), Department of Basic Medical Sciences, Facultad de Medicina, Hospital Universitario HM Sanchinarro, HM Hospitales, Institute of Applied Molecular Medicine (IMMA), Universidad San Pablo CEU, CEU Universities, Madrid, Spain
| | - Miguel Quiralte
- Laboratory of Innovation in Oncology HM CIOCC MADRID (Centro Integral Oncológico Clara Campal), Department of Basic Medical Sciences, Facultad de Medicina, Hospital Universitario HM Sanchinarro, HM Hospitales, Institute of Applied Molecular Medicine (IMMA), Universidad San Pablo CEU, CEU Universities, Madrid, Spain
| | - Massimiliano Zanin
- Instituto de Física Interdisciplinar y Sistemas Complejos IFISC (CSIC-UIB), Palma de Mallorca, Spain
| | - Cristina Rodríguez
- Grupo de Cáncer Endocirno, Centro Nacional de Investigaciones Oncológicas, Madrid, Spain
| | - Paloma Navarro
- Laboratory of Innovation in Oncology HM CIOCC MADRID (Centro Integral Oncológico Clara Campal), Department of Basic Medical Sciences, Facultad de Medicina, Hospital Universitario HM Sanchinarro, HM Hospitales, Institute of Applied Molecular Medicine (IMMA), Universidad San Pablo CEU, CEU Universities, Madrid, Spain
| | - Pedro Berraondo
- Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain
- Navarra Institute for Health Research (IDISNA), Pamplona, Spain
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
| | - Rodrigo Madurga
- Faculty of Experimental Sciences, Universidad Francisco de Vitoria, Madrid, Spain
| |
Collapse
|
4
|
Sevillano E, Madurga R, Rodriguez Moreno JF, Barquin A, Yagüe M, Navarro P, Barba M, Quiralte M, García-Donas J. Prognostic impact of fibroblast growth factor receptor (FGFR) genomic alterations and outcomes in patients with metastatic urothelial. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.6_suppl.537] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
537 Background: FGFR mutations/translocations are druggable targets in metastatic urothelial cancer (mUC). However, the prognostic effect of these genomic alterations (GA) and their role in the response to conventional therapy remain poorly characterized. Methods: We undertook an observational retrospective study in four Academic Hospitals in Madrid, Spain. Clinical and molecular information of patients diagnosed of Urothelial Cancer (UC) between January 2010 and December 2020 was systematically reviewed. The objective of this work was to compare the outcome of mUC patients with GA in the FGFR 2-3 genes versus wild type tumors. Analyses for detection of FGFR translocations and mutations using DNA isolated from formalin-fixed and paraffinized tumor tissue samples consisted of either next-generation sequencing (Foundation One test; n = 68) or qualitative real-time polymerase chain reaction–based assays (n = 9) with TFGFR or QIAGEN therascreen® tests that evaluated somatic mutations within the FGFR2-3 gene: R248C, S249C, G370C and Y373C and fusions: FGFR3-TACC3v3, FGFR3-TACC3v1 and FGFR3-BAIAP2L1, FGFR2-BICC1 and FGFR2-CASP7. Overall response rate (ORR), Progression Free Survival (PFS) and Overall Survival (OS) were determined and Cox-regression analysis were performed to assess the prognostic impact of these alterations. Results: We identified 201 patients diagnosed with UC. Genomic profiling was available in 77 mUC with 28 patients harboring any FGFR GA. Regarding ORR to first line a trend towards a better outcome was identified in FGFR GA (mutation/translocation/fusion) vs wild type cases (57,7% vs 45,5%, p=0,46). However, median OS was significantly worse among FGFR GA (mutation/translocation) vs FGFR wt tumours (13.8 vs 26.2 months, p=0,021). Prognostic factors associated with an unfavorable outcome in multivariable analysis were visceral metastases (HR 7,29 95% CI 1.6-32,3), ECOG >1 (HR 7,03 95% CI 2,59-19,1), first line treatment with checkpoint inhibitors (HR 2,67; 95% CI 1,06-6,74) and the presence of FGFR GAs (HR 2,98, 95% CI 1.37-6.5). Conclusions: Despite a better response to first line treatment, overall FGFR GA showed to be an independent risk factor in mUC. Thus, this determination should be included in new prognostic models.[Table: see text]
Collapse
Affiliation(s)
- Elena Sevillano
- Hospital Universitario Son Espases, Palma De Mallorca, Spain
| | | | | | - Arantzazu Barquin
- HM Hospitales-Centro Integral Oncológico Clara Campal, Madrid, Spain
| | - Monica Yagüe
- HM Hospitales-Centro Integral Oncológico Clara Campal, Madrid, Spain
| | | | - María Barba
- HM Sanchinarro Centro Integral Oncologico Clara Campal (CIOCC), Madrid, Spain
| | | | | |
Collapse
|
5
|
Díaz-Antón B, Madurga R, Zorita B, Wasniewski S, Moreno-Arciniegas A, López-Melgar B, Ramírez Merino N, Martín-Asenjo R, Barrio P, Amado Escañuela MG, Solís J, Parra Jiménez FJ, Ciruelos E, Castellano JM, Fernández-Friera L. Early detection of anthracycline- and trastuzumab-induced cardiotoxicity: value and optimal timing of serum biomarkers and echocardiographic parameters. ESC Heart Fail 2022; 9:1127-1137. [PMID: 35106939 PMCID: PMC8934964 DOI: 10.1002/ehf2.13782] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2021] [Revised: 09/13/2021] [Accepted: 12/14/2021] [Indexed: 01/08/2023] Open
Abstract
AIMS To evaluate echocardiographic and biomarker changes during chemotherapy, assess their ability to early detect and predict cardiotoxicity and to define the best time for their evaluation. METHODS AND RESULTS Seventy-two women with breast cancer (52 ± 9.8 years) treated with anthracyclines (26 also with trastuzumab), were evaluated for 14 months (6 echocardiograms/12 laboratory tests). We analysed: high-sensitivity cardiac troponin T, NT-proBNP, global longitudinal strain (GLS), left ventricle end-systolic volume (LVESV), left ventricle end-diastolic volume (LVEDV), and left ventricular ejection fraction (LVEF). Cardiotoxicity was defined as a reduction in LVEF>10% compared with baseline with LVEF<53%. High-sensitivity troponin T levels rose gradually reaching a maximum peak at 96 ± 13 days after starting chemotherapy (P < 0.001) and 62.5% of patients presented increased values during treatment. NT-proBNP augmented after each anthracycline cycle (mean pre-cycle levels of 72 ± 68 pg/mL and post-cycle levels of 260 ± 187 pg/mL; P < 0.0001). Cardiotoxicity was detected in 9.7% of patients (mean onset at 5.2 months). In the group with cardiotoxicity, the LVESV was higher compared with those without cardiotoxicity (40 mL vs. 29.5 mL; P = 0.045) at 1 month post-anthracycline treatment and the decline in GLS was more pronounced (-17.6% vs. -21.4%; P = 0.03). Trastuzumab did not alter serum biomarkers, but it was associated with an increase in LVESV and LVEDV (P < 0.05). While baseline LVEF was an independent predictor of later cardiotoxicity (P = 0.039), LVESV and GLS resulted to be early detectors of cardiotoxicity [odds ratio = 1.12 (1.02-1.24), odds ratio = 0.66 (0.44-0.92), P < 0.05] at 1 month post-anthracycline treatment. Neither high-sensitivity troponin T nor NT-proBNP was capable of predicting subsequent cardiotoxicity. CONCLUSIONS One month after completion of anthracycline treatment is the optimal time to detect cardiotoxicity by means of imaging parameters (LVESV and GSL) and to determine maximal troponin rise. Baseline LVEF was a predictor of later cardiotoxicity. Trastuzumab therapy does not affect troponin values hence imaging techniques are recommended to detect trastuzumab-induced cardiotoxicity.
Collapse
Affiliation(s)
- Belén Díaz-Antón
- Departamento de Cardiología, HM Hospitales-Centro Integral de Enfermedades Cardiovasculares HM CIEC, Melchor Fernández Almagro 3, Madrid, 28029, Spain.,Unidad de Imagen Cardiaca, HM Hospitales-Centro Integral de Enfermedades Cardiovasculares HM CIEC, Madrid, Spain.,Universidad CEU San Pablo, Madrid, Spain.,Atria Clinic, Madrid, Spain
| | - Rodrigo Madurga
- Fundación de Investigación HM Hospitales, HM Hospitales, Madrid, Spain.,Facultad de Ciencias Experimentales, Universidad Francisco de Vitoria, Madrid, Spain
| | - Blanca Zorita
- Departamento de Cardiología, HM Hospitales-Centro Integral de Enfermedades Cardiovasculares HM CIEC, Melchor Fernández Almagro 3, Madrid, 28029, Spain
| | - Samantha Wasniewski
- Unidad de Imagen Cardiaca, HM Hospitales-Centro Integral de Enfermedades Cardiovasculares HM CIEC, Madrid, Spain
| | - Andrea Moreno-Arciniegas
- Departamento de Cardiología, HM Hospitales-Centro Integral de Enfermedades Cardiovasculares HM CIEC, Melchor Fernández Almagro 3, Madrid, 28029, Spain.,Unidad de Imagen Cardiaca, HM Hospitales-Centro Integral de Enfermedades Cardiovasculares HM CIEC, Madrid, Spain
| | - Beatriz López-Melgar
- Departamento de Cardiología, HM Hospitales-Centro Integral de Enfermedades Cardiovasculares HM CIEC, Melchor Fernández Almagro 3, Madrid, 28029, Spain.,Unidad de Imagen Cardiaca, HM Hospitales-Centro Integral de Enfermedades Cardiovasculares HM CIEC, Madrid, Spain
| | - Natalia Ramírez Merino
- Universidad CEU San Pablo, Madrid, Spain.,Departamento de Oncología Médica, HM Hospitales, Madrid, Spain
| | | | - Patricia Barrio
- Departamento de Cardiología, HM Hospitales-Centro Integral de Enfermedades Cardiovasculares HM CIEC, Melchor Fernández Almagro 3, Madrid, 28029, Spain.,Unidad de Imagen Cardiaca, HM Hospitales-Centro Integral de Enfermedades Cardiovasculares HM CIEC, Madrid, Spain
| | - Maximiliano German Amado Escañuela
- Unidad de Imagen Cardiaca, HM Hospitales-Centro Integral de Enfermedades Cardiovasculares HM CIEC, Madrid, Spain.,Hospital General de Segovia, Segovia, Spain
| | - Jorge Solís
- Atria Clinic, Madrid, Spain.,Servicio de Cardiología, Hospital Universitario 12 de Octubre, Madrid, Spain.,Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.,CIBER de enfermedades CardioVasculares (CIBERCV), Madrid, Spain
| | - Francisco Javier Parra Jiménez
- Departamento de Cardiología, HM Hospitales-Centro Integral de Enfermedades Cardiovasculares HM CIEC, Melchor Fernández Almagro 3, Madrid, 28029, Spain
| | - Eva Ciruelos
- Departamento de Oncología Médica, HM Hospitales, Madrid, Spain.,Servicio Oncología, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - José María Castellano
- Departamento de Cardiología, HM Hospitales-Centro Integral de Enfermedades Cardiovasculares HM CIEC, Melchor Fernández Almagro 3, Madrid, 28029, Spain.,Universidad CEU San Pablo, Madrid, Spain.,Atria Clinic, Madrid, Spain.,Fundación de Investigación HM Hospitales, HM Hospitales, Madrid, Spain.,Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.,CIBER de enfermedades CardioVasculares (CIBERCV), Madrid, Spain
| | - Leticia Fernández-Friera
- Unidad de Imagen Cardiaca, HM Hospitales-Centro Integral de Enfermedades Cardiovasculares HM CIEC, Madrid, Spain.,Universidad CEU San Pablo, Madrid, Spain.,Atria Clinic, Madrid, Spain.,Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.,CIBER de enfermedades CardioVasculares (CIBERCV), Madrid, Spain
| |
Collapse
|
6
|
Crainiciuc G, Palomino-Segura M, Molina-Moreno M, Sicilia J, Aragones DG, Li JLY, Madurga R, Adrover JM, Aroca-Crevillén A, Martin-Salamanca S, Del Valle AS, Castillo SD, Welch HCE, Soehnlein O, Graupera M, Sánchez-Cabo F, Zarbock A, Smithgall TE, Di Pilato M, Mempel TR, Tharaux PL, González SF, Ayuso-Sacido A, Ng LG, Calvo GF, González-Díaz I, Díaz-de-María F, Hidalgo A. Behavioural immune landscapes of inflammation. Nature 2022; 601:415-421. [PMID: 34987220 PMCID: PMC10022527 DOI: 10.1038/s41586-021-04263-y] [Citation(s) in RCA: 42] [Impact Index Per Article: 21.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2021] [Accepted: 11/18/2021] [Indexed: 11/09/2022]
Abstract
Transcriptional and proteomic profiling of individual cells have revolutionized interpretation of biological phenomena by providing cellular landscapes of healthy and diseased tissues1,2. These approaches, however, do not describe dynamic scenarios in which cells continuously change their biochemical properties and downstream 'behavioural' outputs3-5. Here we used 4D live imaging to record tens to hundreds of morpho-kinetic parameters describing the dynamics of individual leukocytes at sites of active inflammation. By analysing more than 100,000 reconstructions of cell shapes and tracks over time, we obtained behavioural descriptors of individual cells and used these high-dimensional datasets to build behavioural landscapes. These landscapes recognized leukocyte identities in the inflamed skin and trachea, and uncovered a continuum of neutrophil states inside blood vessels, including a large, sessile state that was embraced by the underlying endothelium and associated with pathogenic inflammation. Behavioural screening in 24 mouse mutants identified the kinase Fgr as a driver of this pathogenic state, and interference with Fgr protected mice from inflammatory injury. Thus, behavioural landscapes report distinct properties of dynamic environments at high cellular resolution.
Collapse
Affiliation(s)
- Georgiana Crainiciuc
- Area of Cell and Developmental Biology, Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain
| | - Miguel Palomino-Segura
- Area of Cell and Developmental Biology, Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain
| | - Miguel Molina-Moreno
- Department of Signal Processing and Communication, Universidad Carlos III de Madrid, Madrid, Spain
| | - Jon Sicilia
- Area of Cell and Developmental Biology, Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain
- Bioinformatics Unit, Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain
| | - David G Aragones
- Department of Mathematics & MOLAB-Mathematical Oncology Laboratory, Universidad de Castilla-La Mancha, Ciudad Real, Spain
| | - Jackson Liang Yao Li
- Area of Cell and Developmental Biology, Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain
- Singapore Immunology Network (SIgN), A*STAR, Biopolis, Singapore
| | - Rodrigo Madurga
- Faculty of Experimental Sciences and Faculty of Medicine, Universidad Francisco de Vitoria, Madrid, Spain
| | - José M Adrover
- Area of Cell and Developmental Biology, Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain
| | - Alejandra Aroca-Crevillén
- Area of Cell and Developmental Biology, Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain
| | - Sandra Martin-Salamanca
- Area of Cell and Developmental Biology, Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain
| | - Alfonso Serrano Del Valle
- Area of Cell and Developmental Biology, Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain
| | - Sandra D Castillo
- Endothelial Pathobiology and Microenviroment Group, Josep Carreras Leukaemia Research Institute (IJC), 08916 Badalona, Barcelona, Spain
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain
| | | | - Oliver Soehnlein
- Institute for Experimental Pathology, Center for Molecular Biology of Inflammation, Westfälische Wilhelms-Universität, Münster, Germany
| | - Mariona Graupera
- Endothelial Pathobiology and Microenviroment Group, Josep Carreras Leukaemia Research Institute (IJC), 08916 Badalona, Barcelona, Spain
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain
| | - Fátima Sánchez-Cabo
- Bioinformatics Unit, Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain
| | - Alexander Zarbock
- Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany
| | - Thomas E Smithgall
- Department of Microbiology and Molecular Genetics, University of Pittsburgh, School of Medicine, Pittsburgh, PA, USA
| | - Mauro Di Pilato
- Center for Immunology and Inflammatory Diseases at Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
- Department of Immunology, the University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Thorsten R Mempel
- Center for Immunology and Inflammatory Diseases at Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | | | - Santiago F González
- Institute for Research in Biomedicine, Università della Svizzera Italiana, Bellinzona, Switzerland
| | - Angel Ayuso-Sacido
- Faculty of Experimental Sciences and Faculty of Medicine, Universidad Francisco de Vitoria, Madrid, Spain
- Brain Tumor Laboratory, Fundación Vithas, Grupo Hospitales Vithas, Madrid, Spain
| | - Lai Guan Ng
- Singapore Immunology Network (SIgN), A*STAR, Biopolis, Singapore
| | - Gabriel F Calvo
- Department of Mathematics & MOLAB-Mathematical Oncology Laboratory, Universidad de Castilla-La Mancha, Ciudad Real, Spain
| | - Iván González-Díaz
- Department of Signal Processing and Communication, Universidad Carlos III de Madrid, Madrid, Spain
| | - Fernando Díaz-de-María
- Department of Signal Processing and Communication, Universidad Carlos III de Madrid, Madrid, Spain
| | - Andrés Hidalgo
- Area of Cell and Developmental Biology, Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain.
- Vascular Biology and Therapeutics Program and Department of Immunobiology, Yale University School of Medicine, New Haven, USA.
| |
Collapse
|
7
|
Guntiñas A, Galocha C, Madurga R, Kirk J, Usandizaga R, Ángel Rodríguez-Zambrano M. Application of pelvic floor ultrasound during pregnancy to detect patients at risk of cesarean section due to failure of labor progression in a Spanish population. Eur J Obstet Gynecol Reprod Biol 2021; 269:102-107. [PMID: 34979363 DOI: 10.1016/j.ejogrb.2021.12.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2021] [Revised: 11/20/2021] [Accepted: 12/22/2021] [Indexed: 11/25/2022]
Abstract
OBJECTIVE Our study is aimed at evaluating the characteristics of the pelvic floor, assessed through transperineal ultrasound, since it may influence or increase the possibility of having a cesarean delivery, with the objective of acting on those variables that can be modified during pregnancy. STUDY DESIGN Transperineal ultrasound was performed on 109 primiparous pregnant women in their first trimester of pregnancy, recruited between May 2018 and February 2019, with the purpose of studying the hiatus area at rest, retention and Valsalva. We have reassessed them at the end of pregnancy and delivery data were recorded. We selected 8 patients as case-study, who had cesarean section delivery due to failure of labor progression. We selected 4 control-cases for each, reaching the total of 32 controls, with similar age and body mass index, to avoid obtaining a biased result from these data. RESULTS In the study of hiatal areas, patients who delivered by cesarean section had a smaller hiatal area at rest, during levator ani muscle contraction and during Valsalva maneuver, at all visits. In early pregnancy, the range of the resting hiatal area was 13.8 ± 2.0 cm2 for cesarean sections, compared to 16.2 ± 2.7 cm2 for vaginal deliveries with an OR of 0.57 (0.34-0.95, 95% CI). For hiatal area on Valsalva, the OR was 0.55 (0.35-0.88, 95% CI). Therefore, the smaller the hiatal area, the greater the possibility of cesarean section. At the end of pregnancy, between 34 and 36 weeks of gestation, the OR of hiatal area on Valsalva was 0.78 (0.60-1.00, 95% CI). CONCLUSION The hiatus area measured by transperineal ultrasonography at the beginning and at the end of the pregnancy may be useful to identify the patients who are at a higher risk of cesarean delivery due to failure of labor progression.
Collapse
Affiliation(s)
- Alicia Guntiñas
- Department of Obstetrics and Gynaecology, University Hospital HM Puerta del Sur, Avda Carlos V, 70. Móstoles, Madrid 28938, Spain.
| | - Carolina Galocha
- Department of Obstetrics and Gynaecology, University Hospital HM Hospitals, Montepríncipe, Madrid 28660, Spain
| | - Rodrigo Madurga
- Faculty of Experimental Science, Universidad Francisco de Vitoria, Madrid. Spain
| | - Janette Kirk
- Department of Obstetrics and Gynaecology, University Hospital HM Puerta del Sur, Avda Carlos V, 70. Móstoles, Madrid 28938, Spain
| | - Ramón Usandizaga
- Chief of Pelvic Floor Section at Department of Obstetrics and Gynaecology, University Hospital La Paz, Paseo de la Castellana, 261, Madrid 28046, Spain
| | - Miguel Ángel Rodríguez-Zambrano
- Chief of Department of Obstetrics and Gynaecology, University Hospital HM Puerta del Sur, Avda Carlos V, 70. Móstoles, Madrid 282938, Spain
| |
Collapse
|
8
|
Varona JF, Madurga R, Peñalver F, Abarca E, Almirall C, Cruz M, Ramos E, Castellano-Vazquez JM. kinetics of anti-SARS-CoV-2 antibodies over time. Results of 10 month follow up in over 300 seropositive Health Care Workers. Eur J Intern Med 2021; 89:97-103. [PMID: 34090748 PMCID: PMC8148432 DOI: 10.1016/j.ejim.2021.05.028] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/10/2021] [Revised: 05/07/2021] [Accepted: 05/10/2021] [Indexed: 12/11/2022]
Abstract
BACKGROUND The kinetics of the antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) needs to be evaluated since long-term duration of antibody remains largely unknown, particularly in infected healthcare workers (HCW). METHODS Prospective study, evaluating the longitudinal profile of anti-SARS-CoV-2 antibody titers in a random sample of 331 seropositive healthcare workers (HCW) of Spanish Hospitals Group. Serial measurements of serum IgG-anti-SARS-CoV-2 were obtained at baseline (April-May,2020), and in 2 follow-up visits. Linear mixed models were used to investigate antibody kinetics and associated factors. RESULTS A total of 306 seropositive subjects (median age: 44.7years;69.9% female) were included in the final analysis. After a median follow-up of 274 days between baseline and final measurement, 235(76.8%) maintained seropositivity. Antibody titers decreased in 82.0%, while remained stable in 13.1%. Factors associated with stability of antibodies over time included age≥45 years, higher baseline titers, severe/moderate infection and high-grade exposure to COVID-19 patients. In declining profile, estimated mean antibody half-life was 146.3 days(95%CI:138.6-154.9) from baseline. Multivariate models show independent longer durability of antibodies in HCW with high-risk exposure to COVID-19 patients (+14.1 days;95%CI:0.6-40.2) and with symptomatic COVID-19 (+14.1 days;95%CI:0.9-43.0). The estimated mean time to loss antibodies was 375(95% CI:342-408) days from baseline. CONCLUSIONS We present the first study measuring the kinetics of antibody response against SARS-CoV-2 in HCW beyond 6 months. Most participants remained seropositive after 9 months but presented a significant decline in antibody-titers. Two distinct antibody dynamic profiles were observed (declining vs. stable). Independent factors associated with longer durability of antibodies were symptomatic infection and higher exposure to COVID-19 patients.
Collapse
Affiliation(s)
- Jose F Varona
- Departamento de Medicina Interna, Hospital Universitario HM Monteprincipe, HM Hospitales, Madrid, Spain; Facultad de Medicina, Universidad San Pablo-CEU, CEU Universities, Madrid, Spain.
| | - Rodrigo Madurga
- Fundación de Investigación, HM Hospitales, Madrid, Spain; Facultad de Ciencias Experimentales, Universidad Francisco de Vitoria, Madrid, Spain
| | - Francisco Peñalver
- Departamento de Seguridad, Salud y Bienestar de HM Hospitales, Madrid, Spain
| | - Elena Abarca
- Servicio de Laboratorio, HM Hospitales, Madrid, Spain
| | | | - Marta Cruz
- Servicio de Laboratorio, HM Hospitales, Madrid, Spain
| | - Enrique Ramos
- Servicio de Laboratorio, HM Hospitales, Madrid, Spain
| | - Jose María Castellano-Vazquez
- Facultad de Medicina, Universidad San Pablo-CEU, CEU Universities, Madrid, Spain; Fundación de Investigación, HM Hospitales, Madrid, Spain; Departamento de Cardiología, Centro Integral de Enfermedades Cardiovasculares (CIEC), Hospital Universitario HM Monteprincipe, Madrid, Spain; Centro Nacional de Investigaciones Cardiovasculares (CNIC), Instituto de Salud Carlos III, Madrid, Spain
| |
Collapse
|
9
|
López-Escobar A, Madurga R, Castellano JM, Ruiz de Aguiar S, Velázquez S, Bucar M, Jimeno S, Ventura PS. Hemogram as marker of in-hospital mortality in COVID-19. J Investig Med 2021; 69:962-969. [PMID: 33849952 PMCID: PMC8050870 DOI: 10.1136/jim-2021-001810] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/23/2021] [Indexed: 01/08/2023]
Abstract
The clinical impact of COVID-19 disease calls for the identification of routine variables to identify patients at increased risk of death. Current understanding of moderate-to-severe COVID-19 pathophysiology points toward an underlying cytokine release driving a hyperinflammatory and procoagulant state. In this scenario, white blood cells and platelets play a direct role as effectors of such inflammation and thrombotic response. We investigate whether hemogram-derived ratios such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio and the systemic immune-inflammation index may help to identify patients at risk of fatal outcomes. Activated platelets and neutrophils may be playing a decisive role during the thromboinflammatory phase of COVID-19 so, in addition, we introduce and validate a novel marker, the neutrophil-to-platelet ratio (NPR).Two thousand and eighty-eight hospitalized patients with COVID-19 admitted at any of the hospitals of HM Hospitales group in Spain, from March 1 to June 10, 2020, were categorized according to the primary outcome of in-hospital death.Baseline values, as well as the rate of increase of the four ratios analyzed were significantly higher at hospital admission in patients who died than in those who were discharged (p<0.0001). In multivariable logistic regression models, NLR (OR 1.05; 95% CI 1.02 to 1.08, p=0.00035) and NPR (OR 1.23; 95% CI 1.12 to 1.36, p<0.0001) were significantly and independently associated with in-hospital mortality.According to our results, hemogram-derived ratios obtained at hospital admission, as well as the rate of change during hospitalization, may easily detect, primarily using NLR and the novel NPR, patients with COVID-19 at high risk of in-hospital mortality.
Collapse
Affiliation(s)
- Alejandro López-Escobar
- Pediatrics Department, HM Hospitales, Madrid, Spain
- Faculty of Medicine, Universidad San Pablo CEU, Madrid, Spain
- Fundación de Investigación, HM Hospitales, Madrid, Spain
| | - Rodrigo Madurga
- Fundación de Investigación, HM Hospitales, Madrid, Spain
- Faculty of Experimental Sciences, Universidad Francisco de Vitoria, Pozuelo de Alarcon, Comunidad de Madrid, Spain
| | - José María Castellano
- Faculty of Medicine, Universidad San Pablo CEU, Madrid, Spain
- Fundación de Investigación, HM Hospitales, Madrid, Spain
- Cardiology Department, Hospital Universitario HM Montepríncipe, HM Hospitales, Madrid, Spain
| | - Santiago Ruiz de Aguiar
- Fundación de Investigación, HM Hospitales, Madrid, Spain
- Medical Management, HM Hospitales, Madrid, Spain
| | - Sara Velázquez
- Fundación de Investigación, HM Hospitales, Madrid, Spain
- Anaesthesia Department, HM Hospitales, Madrid, Spain
- Anaesthesia Department, Hospital Universitario Santa Cristina, Madrid, Spain
| | - Marina Bucar
- Fundación de Investigación, HM Hospitales, Madrid, Spain
- Internal Medicine Department, HM Hospitales, Madrid, Spain
| | - Sara Jimeno
- Pediatrics Department, HM Hospitales, Madrid, Spain
- Faculty of Medicine, Universidad San Pablo CEU, Madrid, Spain
- Fundación de Investigación, HM Hospitales, Madrid, Spain
| | - Paula Sol Ventura
- Fundación de Investigación, HM Hospitales, Madrid, Spain
- Pediatrics Department Hospital Universitario HM Nens, HM Hospitales, Barcelona, Madrid, Spain
| |
Collapse
|
10
|
Varona JF, Madurga R, Peñalver F, Abarca E, Almirall C, Cruz M, Ramos E, Castellano Vázquez JM. Seroprevalence of SARS-CoV-2 antibodies in over 6000 healthcare workers in Spain. Int J Epidemiol 2021; 50:400-409. [PMID: 33434269 PMCID: PMC7928898 DOI: 10.1093/ije/dyaa277] [Citation(s) in RCA: 39] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2020] [Accepted: 12/14/2020] [Indexed: 01/04/2023] Open
Abstract
Background: Spain has one of the highest incidences of coronavirus disease 2019 (COVID-19) worldwide, so Spanish health care workers (HCW) are at high risk of exposure. Our objective was to determine severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody seroprevalence amongst HCW and factors associated with seropositivity. Methods: A cross-sectional study evaluating 6190 workers (97.8% of the total workforce of a healthcare-system of 17 hospitals across four regions in Spain) was carried out between April and June 2020, by measuring immunoglobulin G (IgG)-SARS-CoV-2 antibody titres and related clinical data. Exposure risk was categorized as high (clinical environment; prolonged/direct contact with patients), moderate (clinical environment; non-intense/no patient contact) and low (non-clinical environment). Results: A total of 6038 employees (mean age 43.8 years; 71% female) were included in the final analysis. A total of 662 (11.0%) were seropositive for IgG against SARS-CoV-2 (39.4% asymptomatic). Adding available PCR-testing, 713 (11.8%) employees showed evidence of previous SARS-CoV-2 infection. However, before antibody testing, 482 of them (67%) had no previous diagnosis of SARS-CoV-2-infection. Seroprevalence was higher in high- and moderate-risk exposure (12.1 and 11.4%, respectively) compared with low-grade risk subjects (7.2%), and in Madrid (13.8%) compared with Barcelona (7.6%) and Coruña (2.0%). High-risk [odds ratio (OR): 2.06; 95% confidence interval (CI): 1.63–2.62] and moderate-risk (OR: 1.77; 95% CI: 1.32–2.37) exposures were associated with positive IgG-SARS-CoV-2 antibodies after adjusting for region, age and sex. Higher antibody titres were observed in moderate–severe disease (median antibody-titre: 13.7 AU/mL) compared with mild (6.4 AU/mL) and asymptomatic (5.1 AU/mL) infection, and also in older (>60 years: 11.8 AU/mL) compared with younger (<30 years: 4.2 AU/mL) people. Conclusions: Seroprevalence of IgG-SARS-CoV-2 antibodies in HCW is a little higher than in the general population and varies depending on regional COVID-19 incidence. The high rates of subclinical and previously undiagnosed infection observed in this study reinforce the utility of antibody screening. An occupational risk for SARS-CoV-2 infection related to working in a clinical environment was demonstrated in this HCW cohort.
Collapse
Affiliation(s)
- Jose F Varona
- Departamento de Medicina Interna, Hospital Universitario HM Montepríncipe, HM Hospitales, Madrid, Spain.,Facultad de Medicina, Universidad San Pablo-CEU, CEU Universities, Madrid, Spain
| | - Rodrigo Madurga
- Fundación de Investigación HM Hospitales, HM Hospitales, Madrid, Spain.,Facultad de Ciencias Experimentales, Universidad Francisco de Vitoria, Madrid, Spain
| | - Francisco Peñalver
- Departamento de Seguridad, Salud y Bienestar, HM Hospitales, Madrid, Spain
| | - Elena Abarca
- Departamento de Laboratorio, HM Hospitales, Madrid, Spain
| | | | - Marta Cruz
- Departamento de Laboratorio, HM Hospitales, Madrid, Spain
| | - Enrique Ramos
- Departamento de Laboratorio, HM Hospitales, Madrid, Spain
| | - Jose María Castellano Vázquez
- Facultad de Medicina, Universidad San Pablo-CEU, CEU Universities, Madrid, Spain.,Fundación de Investigación HM Hospitales, HM Hospitales, Madrid, Spain
| |
Collapse
|
11
|
Duraj T, García-Romero N, Carrión-Navarro J, Madurga R, Ortiz de Mendivil A, Prat-Acin R, Garcia-Cañamaque L, Ayuso-Sacido A. Beyond the Warburg Effect: Oxidative and Glycolytic Phenotypes Coexist within the Metabolic Heterogeneity of Glioblastoma. Cells 2021; 10:202. [PMID: 33498369 PMCID: PMC7922554 DOI: 10.3390/cells10020202] [Citation(s) in RCA: 41] [Impact Index Per Article: 13.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2020] [Revised: 01/16/2021] [Accepted: 01/18/2021] [Indexed: 12/12/2022] Open
Abstract
Glioblastoma (GBM) is the most aggressive primary brain tumor, with a median survival at diagnosis of 16-20 months. Metabolism represents a new attractive therapeutic target; however, due to high intratumoral heterogeneity, the application of metabolic drugs in GBM is challenging. We characterized the basal bioenergetic metabolism and antiproliferative potential of metformin (MF), dichloroacetate (DCA), sodium oxamate (SOD) and diazo-5-oxo-L-norleucine (DON) in three distinct glioma stem cells (GSCs) (GBM18, GBM27, GBM38), as well as U87MG. GBM27, a highly oxidative cell line, was the most resistant to all treatments, except DON. GBM18 and GBM38, Warburg-like GSCs, were sensitive to MF and DCA, respectively. Resistance to DON was not correlated with basal metabolic phenotypes. In combinatory experiments, radiomimetic bleomycin exhibited therapeutically relevant synergistic effects with MF, DCA and DON in GBM27 and DON in all other cell lines. MF and DCA shifted the metabolism of treated cells towards glycolysis or oxidation, respectively. DON consistently decreased total ATP production. Our study highlights the need for a better characterization of GBM from a metabolic perspective. Metabolic therapy should focus on both glycolytic and oxidative subpopulations of GSCs.
Collapse
Affiliation(s)
- Tomás Duraj
- Faculty of Medicine, Institute for Applied Molecular Medicine (IMMA), CEU San Pablo University, 28668 Madrid, Spain;
| | - Noemí García-Romero
- Faculty of Experimental Sciences, Universidad Francisco de Vitoria, 28223 Madrid, Spain; (N.G.-R.); (J.C.-N.); (R.M.)
- Brain Tumor Laboratory, Fundación Vithas, Grupo Hospitales Vithas, 28043 Madrid, Spain
| | - Josefa Carrión-Navarro
- Faculty of Experimental Sciences, Universidad Francisco de Vitoria, 28223 Madrid, Spain; (N.G.-R.); (J.C.-N.); (R.M.)
- Brain Tumor Laboratory, Fundación Vithas, Grupo Hospitales Vithas, 28043 Madrid, Spain
| | - Rodrigo Madurga
- Faculty of Experimental Sciences, Universidad Francisco de Vitoria, 28223 Madrid, Spain; (N.G.-R.); (J.C.-N.); (R.M.)
- Brain Tumor Laboratory, Fundación Vithas, Grupo Hospitales Vithas, 28043 Madrid, Spain
| | | | - Ricardo Prat-Acin
- Neurosurgery Department, Hospital Universitario La Fe, 46026 Valencia, Spain;
| | | | - Angel Ayuso-Sacido
- Faculty of Experimental Sciences, Universidad Francisco de Vitoria, 28223 Madrid, Spain; (N.G.-R.); (J.C.-N.); (R.M.)
- Brain Tumor Laboratory, Fundación Vithas, Grupo Hospitales Vithas, 28043 Madrid, Spain
| |
Collapse
|
12
|
Peinado P, Sanz Garcia E, Moreno I, Dorta M, Alvarez B, Alvarez Gallego R, Madurga R, Ugidos L, Rodriguez Pascual J, Muñoz C, Garcia-Rico E, Cubillo A. 1760P COVID-19 severe pneumonia in cancer patients: Impact and predictive factors. Ann Oncol 2020. [PMCID: PMC7506389 DOI: 10.1016/j.annonc.2020.08.1824] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022] Open
|
13
|
Madurga R, García-Romero N, Jiménez B, Collazo A, Pérez-Rodríguez F, Hernández-Laín A, Fernández-Carballal C, Prat-Acín R, Zanin M, Menasalvas E, Ayuso-Sacido Á. Normal tissue content impact on the GBM molecular classification. Brief Bioinform 2020; 22:5868069. [PMID: 32632447 DOI: 10.1093/bib/bbaa129] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2020] [Revised: 05/18/2020] [Accepted: 05/26/2020] [Indexed: 12/19/2022] Open
Abstract
Molecular classification of glioblastoma has enabled a deeper understanding of the disease. The four-subtype model (including Proneural, Classical, Mesenchymal and Neural) has been replaced by a model that discards the Neural subtype, found to be associated with samples with a high content of normal tissue. These samples can be misclassified preventing biological and clinical insights into the different tumor subtypes from coming to light. In this work, we present a model that tackles both the molecular classification of samples and discrimination of those with a high content of normal cells. We performed a transcriptomic in silico analysis on glioblastoma (GBM) samples (n = 810) and tested different criteria to optimize the number of genes needed for molecular classification. We used gene expression of normal brain samples (n = 555) to design an additional gene signature to detect samples with a high normal tissue content. Microdissection samples of different structures within GBM (n = 122) have been used to validate the final model. Finally, the model was tested in a cohort of 43 patients and confirmed by histology. Based on the expression of 20 genes, our model is able to discriminate samples with a high content of normal tissue and to classify the remaining ones. We have shown that taking into consideration normal cells can prevent errors in the classification and the subsequent misinterpretation of the results. Moreover, considering only samples with a low content of normal cells, we found an association between the complexity of the samples and survival for the three molecular subtypes.
Collapse
Affiliation(s)
- Rodrigo Madurga
- Biostatistics and Bioinformatics at Fundación de Investigación HM Hospitales and Professor at the Faculty of Experimental Sciences of the Universidad Francisco de Vitoria
| | - Noemí García-Romero
- Molecular Biology at Fundación Vithas and professor at Francisco de Vitoria University
| | | | | | | | | | | | | | | | - Ernestina Menasalvas
- Department of Computer Systems Languages and Software Engineering at the Faculty of Computer Science of Universidad Politecnica de Madrid
| | - Ángel Ayuso-Sacido
- Brain Tumour Laboratory, Scientific Director at Vithas Hospitals, Managing Director at Fundación Vithas and Professor at the Medial School of Francisco de Vitoria University
| |
Collapse
|
14
|
García-Romero N, Palacín-Aliana I, Madurga R, Carrión-Navarro J, Esteban-Rubio S, Jiménez B, Collazo A, Pérez-Rodríguez F, Ortiz de Mendivil A, Fernández-Carballal C, García-Duque S, Diamantopoulos-Fernández J, Belda-Iniesta C, Prat-Acín R, Sánchez-Gómez P, Calvo E, Ayuso-Sacido A. Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma. BMC Med 2020; 18:142. [PMID: 32564774 PMCID: PMC7310142 DOI: 10.1186/s12916-020-01610-0] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/22/2019] [Accepted: 04/29/2020] [Indexed: 01/02/2023] Open
Abstract
BACKGROUND Glioblastoma (GBM) is one of the most aggressive and vascularized brain tumors in adults, with a median survival of 20.9 months. In newly diagnosed and recurrent GBM, bevacizumab demonstrated an increase in progression-free survival, but not in overall survival. METHODS We conducted an in silico analysis of VEGF expression, in a cohort of 1082 glioma patients. Then, to determine whether appropriate bevacizumab dose adjustment could increase the anti-angiogenic response, we used in vitro and in vivo GBM models. Additionally, we analyzed VEGFA expression in tissue, serum, and plasma in a cohort of GBM patients before and during bevacizumab treatment. RESULTS We identified that 20% of primary GBM did not express VEGFA suggesting that these patients would probably not respond to bevacizumab therapy as we proved in vitro and in vivo. We found that a specific dose of bevacizumab calculated based on VEGFA expression levels increases the response to treatment in cell culture and serum samples from mice bearing GBM tumors. Additionally, in a cohort of GBM patients, we observed a correlation of VEGFA levels in serum, but not in plasma, with bevacizumab treatment performance. CONCLUSIONS Our data suggest that bevacizumab dose adjustment could improve clinical outcomes in Glioblastoma treatment.
Collapse
Affiliation(s)
- N García-Romero
- Fundación de Investigación HM Hospitales, HM Hospitales, Madrid, Spain.,Faculty of Experimental Sciences, Universidad Francisco de Vitoria, Pozuelo de Alarcón, Madrid, 28223, Spain
| | - I Palacín-Aliana
- Fundación de Investigación HM Hospitales, HM Hospitales, Madrid, Spain.,Atrys Health, Barcelona, 08025, Spain
| | - R Madurga
- Fundación de Investigación HM Hospitales, HM Hospitales, Madrid, Spain.,Faculty of Experimental Sciences, Universidad Francisco de Vitoria, Pozuelo de Alarcón, Madrid, 28223, Spain
| | - J Carrión-Navarro
- Faculty of Experimental Sciences, Universidad Francisco de Vitoria, Pozuelo de Alarcón, Madrid, 28223, Spain.,Fundación Vithas, Vithas Hospitals, Madrid, 28043, Spain.,Formerly: Fundación de Investigación HM Hospitales, HM Hospitales, Madrid, Spain
| | - S Esteban-Rubio
- Formerly: Facultad de Medicina (IMMA), Universidad San Pablo-CEU, Madrid, Spain
| | - B Jiménez
- Fundación de Investigación HM Hospitales, HM Hospitales, Madrid, Spain
| | - A Collazo
- Fundación de Investigación HM Hospitales, HM Hospitales, Madrid, Spain
| | - F Pérez-Rodríguez
- Fundación de Investigación HM Hospitales, HM Hospitales, Madrid, Spain
| | | | - C Fernández-Carballal
- Servicio de Neurocirugía, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - S García-Duque
- Fundación de Investigación HM Hospitales, HM Hospitales, Madrid, Spain
| | | | - C Belda-Iniesta
- Fundación de Investigación HM Hospitales, HM Hospitales, Madrid, Spain
| | - R Prat-Acín
- Departamento de Neurocirugía, Hospital Universitario la Fe, Valencia, Spain
| | - P Sánchez-Gómez
- Neuro-oncology Unit, Instituto de Salud Carlos III-UFIEC, Madrid, Spain
| | - E Calvo
- Fundación de Investigación HM Hospitales, HM Hospitales, Madrid, Spain.,START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain
| | - A Ayuso-Sacido
- Faculty of Experimental Sciences, Universidad Francisco de Vitoria, Pozuelo de Alarcón, Madrid, 28223, Spain. .,Fundación Vithas, Vithas Hospitals, Madrid, 28043, Spain. .,Formerly: Fundación de Investigación HM Hospitales, HM Hospitales, Madrid, Spain. .,Formerly: Facultad de Medicina (IMMA), Universidad San Pablo-CEU, Madrid, Spain. .,Formerly: Facultad de Medicina (IMMA), Universidad San Pablo-CEU, Madrid, Spain.
| |
Collapse
|
15
|
García-Romero N, Carrión-Navarro J, Areal-Hidalgo P, Ortiz de Mendivil A, Asensi-Puig A, Madurga R, Núñez-Torres R, González-Neira A, Belda-Iniesta C, González-Rumayor V, López-Ibor B, Ayuso-Sacido A. BRAF V600E Detection in Liquid Biopsies from Pediatric Central Nervous System Tumors. Cancers (Basel) 2019; 12:cancers12010066. [PMID: 31881643 PMCID: PMC7016762 DOI: 10.3390/cancers12010066] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2019] [Revised: 12/14/2019] [Accepted: 12/19/2019] [Indexed: 12/17/2022] Open
Abstract
Pediatric Central Nervous System (CNS) tumors are the most fatal cancer diseases in childhood. Due to their localization and infiltrative nature, some tumor resections or biopsies are not feasible. In those cases, the use of minimally invasive methods as diagnostic, molecular marker detection, prognostic or monitoring therapies are emerging. The analysis of liquid biopsies which contain genetic information from the tumor has been much more widely explored in adults than in children. We compare the detection of BRAF V600E targetable mutation by digital-PCR from cell-free-DNA and EV-derived DNA (ctDNA) in serum, plasma and cerebrospinal fluid (CSF) isolated from a cohort of 29 CNS pediatric patients. Here we demonstrate that ctDNA isolated from serum and plasma could be successfully analyzed to obtain tumor genetic information which could be used to guide critical treatment decisions.
Collapse
Affiliation(s)
- Noemi García-Romero
- Fundación de Investigación HM Hospitales, HM Hospitales, 28015 Madrid, Spain; (N.G.-R.); (J.C.-N.); (P.A.-H.); (A.O.d.M.); (R.M.); (C.B.-I.)
| | - Josefa Carrión-Navarro
- Fundación de Investigación HM Hospitales, HM Hospitales, 28015 Madrid, Spain; (N.G.-R.); (J.C.-N.); (P.A.-H.); (A.O.d.M.); (R.M.); (C.B.-I.)
| | - Pilar Areal-Hidalgo
- Fundación de Investigación HM Hospitales, HM Hospitales, 28015 Madrid, Spain; (N.G.-R.); (J.C.-N.); (P.A.-H.); (A.O.d.M.); (R.M.); (C.B.-I.)
- Pediatric Hematology and Oncology Unit, Madrid Montepríncipe Hospital, 28660 Madrid, Spain
| | - Ana Ortiz de Mendivil
- Fundación de Investigación HM Hospitales, HM Hospitales, 28015 Madrid, Spain; (N.G.-R.); (J.C.-N.); (P.A.-H.); (A.O.d.M.); (R.M.); (C.B.-I.)
| | | | - Rodrigo Madurga
- Fundación de Investigación HM Hospitales, HM Hospitales, 28015 Madrid, Spain; (N.G.-R.); (J.C.-N.); (P.A.-H.); (A.O.d.M.); (R.M.); (C.B.-I.)
| | - Rocio Núñez-Torres
- Spanish National Cancer Research Center (CNIO), 28029 Madrid, Spain; (R.N.-T.); (A.G.-N.)
| | - Anna González-Neira
- Spanish National Cancer Research Center (CNIO), 28029 Madrid, Spain; (R.N.-T.); (A.G.-N.)
| | - Cristobal Belda-Iniesta
- Fundación de Investigación HM Hospitales, HM Hospitales, 28015 Madrid, Spain; (N.G.-R.); (J.C.-N.); (P.A.-H.); (A.O.d.M.); (R.M.); (C.B.-I.)
| | | | - Blanca López-Ibor
- Fundación de Investigación HM Hospitales, HM Hospitales, 28015 Madrid, Spain; (N.G.-R.); (J.C.-N.); (P.A.-H.); (A.O.d.M.); (R.M.); (C.B.-I.)
- Pediatric Hematology and Oncology Unit, Madrid Montepríncipe Hospital, 28660 Madrid, Spain
- Correspondence: (B.L.-I.); (A.A.-S.); Tel.: +34-91372-4700 (A.A.-S.)
| | - Angel Ayuso-Sacido
- Fundación de Investigación HM Hospitales, HM Hospitales, 28015 Madrid, Spain; (N.G.-R.); (J.C.-N.); (P.A.-H.); (A.O.d.M.); (R.M.); (C.B.-I.)
- Facultad de Medicina (IMMA), Universidad San Pablo-CEU, 28668 Madrid, Spain
- Correspondence: (B.L.-I.); (A.A.-S.); Tel.: +34-91372-4700 (A.A.-S.)
| |
Collapse
|
16
|
García-Romero N, Madurga R, Rackov G, Palacín-Aliana I, Núñez-Torres R, Asensi-Puig A, Carrión-Navarro J, Esteban-Rubio S, Peinado H, González-Neira A, González-Rumayor V, Belda-Iniesta C, Ayuso-Sacido A. Polyethylene glycol improves current methods for circulating extracellular vesicle-derived DNA isolation. J Transl Med 2019; 17:75. [PMID: 30871557 PMCID: PMC6419425 DOI: 10.1186/s12967-019-1825-3] [Citation(s) in RCA: 45] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2018] [Accepted: 03/01/2019] [Indexed: 12/31/2022] Open
Abstract
Background Extracellular vesicles (EVs) are small membrane-bound vesicles which play an important role in cell-to-cell communication. Their molecular cargo analysis is presented as a new source for biomarker detection, and it might provide an alternative to traditional solid biopsies. However, the most effective approach for EV isolation is not yet well established. Results Here, we study the efficiency of the most common EV isolation methods-ultracentrifugation, Polyethlyene glycol and two commercial kits, Exoquick® and PureExo®. We isolated circulating EVs from the bloodstream of healthy donors, characterized the size and yield of EVs and analyzed their protein profiles and concentration. Moreover, we have used for the first time Digital-PCR to identify and detect specific gDNA sequences, which has several implications for diagnostic and monitoring many types of diseases. Conclusions Our findings present Polyethylene glycol precipitation as the most feasible and less cost-consuming EV isolation technique.
Collapse
Affiliation(s)
- N García-Romero
- Fundación de Investigación HM Hospitales, HM Hospitales, C/Oña 10, 28050, Madrid, Spain
| | - R Madurga
- Fundación de Investigación HM Hospitales, HM Hospitales, C/Oña 10, 28050, Madrid, Spain
| | - G Rackov
- Fundación de Investigación HM Hospitales, HM Hospitales, C/Oña 10, 28050, Madrid, Spain.,IMDEA Nanoscience, Madrid, Spain
| | - I Palacín-Aliana
- Fundación de Investigación HM Hospitales, HM Hospitales, C/Oña 10, 28050, Madrid, Spain
| | - R Núñez-Torres
- Spanish National Cancer Research Center (CNIO), 28029, Madrid, Spain
| | | | - J Carrión-Navarro
- Fundación de Investigación HM Hospitales, HM Hospitales, C/Oña 10, 28050, Madrid, Spain
| | - S Esteban-Rubio
- Fundación de Investigación HM Hospitales, HM Hospitales, C/Oña 10, 28050, Madrid, Spain.,Facultad de Medicina (IMMA), Universidad San Pablo-CEU, Madrid, Spain
| | - H Peinado
- Spanish National Cancer Research Center (CNIO), 28029, Madrid, Spain
| | - A González-Neira
- Spanish National Cancer Research Center (CNIO), 28029, Madrid, Spain
| | | | - C Belda-Iniesta
- Fundación de Investigación HM Hospitales, HM Hospitales, C/Oña 10, 28050, Madrid, Spain
| | - A Ayuso-Sacido
- Fundación de Investigación HM Hospitales, HM Hospitales, C/Oña 10, 28050, Madrid, Spain. .,Facultad de Medicina (IMMA), Universidad San Pablo-CEU, Madrid, Spain.
| |
Collapse
|
17
|
Pérez-Rigueiro J, Madurga R, Gañán-Calvo AM, Elices M, Guinea GV, Tasei Y, Nishimura A, Matsuda H, Asakura T. Emergence of supercontraction in regenerated silkworm (Bombyx mori) silk fibers. Sci Rep 2019; 9:2398. [PMID: 30787337 PMCID: PMC6382804 DOI: 10.1038/s41598-019-38712-6] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2018] [Accepted: 12/17/2018] [Indexed: 12/01/2022] Open
Abstract
The conditions required for the emergence of supercontraction in regenerated silkworm (Bombyx mori) silk fibers are assessed through an experimental approach that combines the spinning of regenerated fibers with controlled properties and their characterization by 13C solid-state nuclear magnetic resonance (NMR). Both supercontracting and non-supercontracting regenerated fibers are produced using the straining flow spinning (SFS) technique from 13C labeled cocoons. The short-range microstructure of the fibers is assessed through 13C CP/MAS in air and 13C DD/MAS in water, and the main microstructural features are identified and quantified. The mechanical properties of the regenerated fibers and their microstructures are compared with those of natural silkworm silk. The combined analysis highlights two possible key elements as responsible for the emergence of supercontraction: (1) the existence of an upper and a lower limit of the amorphous phase compatible with supercontraction, and (2) the existence of two ordered phases, β-sheet A and B, which correspond to different packing arrangements of the protein chains.
Collapse
Affiliation(s)
- José Pérez-Rigueiro
- Centro de Tecnología Biomédica, Universidad Politécnica de Madrid, 28223, Pozuelo de Alarcón, (Madrid), Spain. .,Departamento de Ciencia de Materiales, ETSI Caminos, Canales y Puertos, Universidad Politécnica de Madrid, 28040, Madrid, Spain. .,Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain.
| | - Rodrigo Madurga
- Centro de Tecnología Biomédica, Universidad Politécnica de Madrid, 28223, Pozuelo de Alarcón, (Madrid), Spain.,Departamento de Ciencia de Materiales, ETSI Caminos, Canales y Puertos, Universidad Politécnica de Madrid, 28040, Madrid, Spain
| | - Alfonso M Gañán-Calvo
- Escuela Técnica Superior de Ingenieros, Universidad de Sevilla, 41092, Sevilla, Spain
| | - Manuel Elices
- Centro de Tecnología Biomédica, Universidad Politécnica de Madrid, 28223, Pozuelo de Alarcón, (Madrid), Spain.,Departamento de Ciencia de Materiales, ETSI Caminos, Canales y Puertos, Universidad Politécnica de Madrid, 28040, Madrid, Spain
| | - Gustavo V Guinea
- Centro de Tecnología Biomédica, Universidad Politécnica de Madrid, 28223, Pozuelo de Alarcón, (Madrid), Spain.,Departamento de Ciencia de Materiales, ETSI Caminos, Canales y Puertos, Universidad Politécnica de Madrid, 28040, Madrid, Spain.,Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain
| | - Yugo Tasei
- Department of Biotechnology, Tokyo University of Agriculture and Technology, 2-24-16 Nakacho, Koganei, Tokyo, 184-8588, Japan
| | - Akio Nishimura
- Department of Biotechnology, Tokyo University of Agriculture and Technology, 2-24-16 Nakacho, Koganei, Tokyo, 184-8588, Japan
| | - Hironori Matsuda
- Department of Biotechnology, Tokyo University of Agriculture and Technology, 2-24-16 Nakacho, Koganei, Tokyo, 184-8588, Japan
| | - Tetsuo Asakura
- Department of Biotechnology, Tokyo University of Agriculture and Technology, 2-24-16 Nakacho, Koganei, Tokyo, 184-8588, Japan.
| |
Collapse
|
18
|
Pérez-Rigueiro J, Madurga R, Gañán-Calvo AM, Plaza GR, Elices M, López PA, Daza R, González-Nieto D, Guinea GV. Straining Flow Spinning of Artificial Silk Fibers: A Review. Biomimetics (Basel) 2018; 3:E29. [PMID: 31105251 PMCID: PMC6352662 DOI: 10.3390/biomimetics3040029] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2018] [Revised: 09/13/2018] [Accepted: 10/01/2018] [Indexed: 11/16/2022] Open
Abstract
This work summarizes the main principles and some of the most significant results of straining flow spinning (SFS), a technology developed originally by the authors of this work. The principles on which the technology is based, inspired by the natural spinning system of silkworms and spiders, are presented, as well as some of the main achievements of the technique. Among these achievements, spinning under environmentally friendly conditions, obtaining high-performance fibers, and imparting the fibers with emerging properties such as supercontraction are discussed. Consequently, SFS appears as an efficient process that may represent one of the first realizations of a biomimetic technology with a significant impact at the production level.
Collapse
Affiliation(s)
- José Pérez-Rigueiro
- Centro de Tecnología Biomédica, Universidad Politécnica de Madrid, 28223 Pozuelo de Alarcón, Madrid, Spain.
- Departamento de Ciencia de Materiales, ETSI Caminos, Canales y Puertos, Universidad Politécnica de Madrid, 28040 Madrid, Spain.
- Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain.
| | - Rodrigo Madurga
- Centro de Tecnología Biomédica, Universidad Politécnica de Madrid, 28223 Pozuelo de Alarcón, Madrid, Spain.
- Departamento de Ciencia de Materiales, ETSI Caminos, Canales y Puertos, Universidad Politécnica de Madrid, 28040 Madrid, Spain.
| | - Alfonso M Gañán-Calvo
- Departamento de Ingeniería Aeroespacial y Mecánica de Fluidos, Escuela Técnica Superior de Ingenieros, Universidad de Sevilla, 41092 Sevilla, Spain.
| | - Gustavo R Plaza
- Centro de Tecnología Biomédica, Universidad Politécnica de Madrid, 28223 Pozuelo de Alarcón, Madrid, Spain.
- Departamento de Ciencia de Materiales, ETSI Caminos, Canales y Puertos, Universidad Politécnica de Madrid, 28040 Madrid, Spain.
| | - Manuel Elices
- Centro de Tecnología Biomédica, Universidad Politécnica de Madrid, 28223 Pozuelo de Alarcón, Madrid, Spain.
- Departamento de Ciencia de Materiales, ETSI Caminos, Canales y Puertos, Universidad Politécnica de Madrid, 28040 Madrid, Spain.
| | - Patricia A López
- Centro de Tecnología Biomédica, Universidad Politécnica de Madrid, 28223 Pozuelo de Alarcón, Madrid, Spain.
- Departamento de Ciencia de Materiales, ETSI Caminos, Canales y Puertos, Universidad Politécnica de Madrid, 28040 Madrid, Spain.
| | - Rafael Daza
- Centro de Tecnología Biomédica, Universidad Politécnica de Madrid, 28223 Pozuelo de Alarcón, Madrid, Spain.
- Departamento de Ciencia de Materiales, ETSI Caminos, Canales y Puertos, Universidad Politécnica de Madrid, 28040 Madrid, Spain.
| | - Daniel González-Nieto
- Centro de Tecnología Biomédica, Universidad Politécnica de Madrid, 28223 Pozuelo de Alarcón, Madrid, Spain.
- Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain.
- Departamento de Tecnología Fotónica y Bioingeniería, ETSI Telecomunicaciones, Universidad Politécnica de Madrid, 28040 Madrid, Spain.
| | - Gustavo V Guinea
- Centro de Tecnología Biomédica, Universidad Politécnica de Madrid, 28223 Pozuelo de Alarcón, Madrid, Spain.
- Departamento de Ciencia de Materiales, ETSI Caminos, Canales y Puertos, Universidad Politécnica de Madrid, 28040 Madrid, Spain.
- Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain.
| |
Collapse
|
19
|
Urbano-Bojorge AL, Casanova-Carvajal O, Félix-González N, Fernández L, Madurga R, Sánchez-Cabezas S, Aznar E, Ramos M, Serrano-Olmedo JJ. Influence of medium viscosity and intracellular environment on the magnetization of superparamagnetic nanoparticles in silk fibroin solutions and 3T3 mouse fibroblast cell cultures. Nanotechnology 2018; 29:385705. [PMID: 29947336 DOI: 10.1088/1361-6528/aacf4a] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
Biomedical applications based on the magnetic properties of superparamagnetic iron oxide nanoparticles (SPIONs) may be altered by the mechanical attachment or cellular uptake of these nanoparticles. When nanoparticles interact with living cells, they are captured and internalized into intracellular compartments. Consequently, the magnetic behavior of the nanoparticles is modified. In this paper, we investigated the change in the magnetic response of 14 nm magnetic nanoparticles (Fe3O4) in different solutions, both as a stable liquid suspension (one of them mimicking the cellular cytoplasm) and when associated with cells. The field-dependent magnetization curves from inert fluids and cell cultures were determined by using an alternating gradient magnetometer, MicroMagTM 2900. The equipment was adapted to measure liquid samples because it was originally designed only for solids. In order to achieve this goal, custom sample holders were manufactured. Likewise, the nuclear magnetic relaxation dispersion profiles for the inert fluid were also measured by fast field cycling nuclear magnetic relaxation relaxometry. The results show that SPION magnetization in inert fluids was affected by the carrier liquid viscosity and the concentration. In cell cultures, the mechanical attachment or confinement of the SPIONs inside the cells accounted for the change in the dynamic magnetic behavior of the nanoparticles. Nevertheless, the magnetization value in the cell cultures was slightly lower than that of the fluid simulating the viscosity of cytoplasm, suggesting that magnetization loss was not only due to medium viscosity but also to a reduction in the mechanical degrees of freedom of SPIONs rotation and translation inside cells. The findings presented here provide information on the loss of magnetic properties when nanoparticles are suspended in viscous fluids or internalized in cells. This information could be exploited to improve biomedical applications based on magnetic properties such as magnetic hyperthermia, contrast agents and drug delivery.
Collapse
Affiliation(s)
- Ana Lorena Urbano-Bojorge
- Centro de Tecnología Biomédica (CTB), Universidad Politécnica de Madrid (UPM), Campus de Montegancedo, 28223, Pozuelo de Alarcón, Madrid, Spain. Centro de Investigación Biomédica en Red Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), C/Monforte de Lemos 3-5, Pabellón 11, 28029, Madrid, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Madurga R, Guinea GV, Elices M, Pérez-Rigueiro J, Gañán-Calvo AM. Straining flow spinning: Simplified model of a bioinspired process to mass produce regenerated silk fibers controllably. Eur Polym J 2017. [DOI: 10.1016/j.eurpolymj.2017.09.037] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
21
|
Madurga R, Gañán-Calvo AM, Plaza GR, Guinea GV, Elices M, Pérez-Rigueiro J. Production of High Performance Bioinspired Silk Fibers by Straining Flow Spinning. Biomacromolecules 2017; 18:1127-1133. [DOI: 10.1021/acs.biomac.6b01757] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Rodrigo Madurga
- Centro
de Tecnología Biomédica, Universidad Politécnica de Madrid, 28223 Pozuelo de Alarcón (Madrid), Spain
- Departamento
de Ciencia de Materiales, ETSI Caminos, Canales y Puertos, Universidad Politécnica de Madrid, 28040 Madrid, Spain
| | | | - Gustavo R. Plaza
- Centro
de Tecnología Biomédica, Universidad Politécnica de Madrid, 28223 Pozuelo de Alarcón (Madrid), Spain
- Departamento
de Ciencia de Materiales, ETSI Caminos, Canales y Puertos, Universidad Politécnica de Madrid, 28040 Madrid, Spain
| | - Gustavo V. Guinea
- Centro
de Tecnología Biomédica, Universidad Politécnica de Madrid, 28223 Pozuelo de Alarcón (Madrid), Spain
- Departamento
de Ciencia de Materiales, ETSI Caminos, Canales y Puertos, Universidad Politécnica de Madrid, 28040 Madrid, Spain
- Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain
| | - Manuel Elices
- Centro
de Tecnología Biomédica, Universidad Politécnica de Madrid, 28223 Pozuelo de Alarcón (Madrid), Spain
- Departamento
de Ciencia de Materiales, ETSI Caminos, Canales y Puertos, Universidad Politécnica de Madrid, 28040 Madrid, Spain
| | - José Pérez-Rigueiro
- Centro
de Tecnología Biomédica, Universidad Politécnica de Madrid, 28223 Pozuelo de Alarcón (Madrid), Spain
- Departamento
de Ciencia de Materiales, ETSI Caminos, Canales y Puertos, Universidad Politécnica de Madrid, 28040 Madrid, Spain
- Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain
| |
Collapse
|
22
|
Madurga R, Plaza GR, Blackledge TA, Guinea GV, Elices M, Pérez-Rigueiro J. Material properties of evolutionary diverse spider silks described by variation in a single structural parameter. Sci Rep 2016; 6:18991. [PMID: 26755434 PMCID: PMC4709512 DOI: 10.1038/srep18991] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2015] [Accepted: 11/06/2015] [Indexed: 11/24/2022] Open
Abstract
Spider major ampullate gland silks (MAS) vary greatly in material properties among species but, this variation is shown here to be confined to evolutionary shifts along a single universal performance trajectory. This reveals an underlying design principle that is maintained across large changes in both spider ecology and silk chemistry. Persistence of this design principle becomes apparent after the material properties are defined relative to the true alignment parameter, which describes the orientation and stretching of the protein chains in the silk fiber. Our results show that the mechanical behavior of all Entelegynae major ampullate silk fibers, under any conditions, are described by this single parameter that connects the sequential action of three deformation micromechanisms during stretching: stressing of protein-protein hydrogen bonds, rotation of the β-nanocrystals and growth of the ordered fraction. Conservation of these traits for over 230 million years is an indication of the optimal design of the material and gives valuable clues for the production of biomimetic counterparts based on major ampullate spider silk.
Collapse
Affiliation(s)
- Rodrigo Madurga
- Centro de Tecnología Biomédica. Universidad Politécnica de Madrid. 28223 Pozuelo de Alarcón (Madrid). Spain.,Departamento de Ciencia de Materiales. ETSI Caminos, Canales y Puertos. Universidad Politécnica de Madrid. 28040. Madrid. Spain
| | - Gustavo R Plaza
- Centro de Tecnología Biomédica. Universidad Politécnica de Madrid. 28223 Pozuelo de Alarcón (Madrid). Spain.,Departamento de Ciencia de Materiales. ETSI Caminos, Canales y Puertos. Universidad Politécnica de Madrid. 28040. Madrid. Spain
| | - Todd A Blackledge
- Department of Biology and Integrated Bioscience Program. The University of Akron, Akron, OH44325-3908. USA
| | - Gustavo V Guinea
- Centro de Tecnología Biomédica. Universidad Politécnica de Madrid. 28223 Pozuelo de Alarcón (Madrid). Spain.,Departamento de Ciencia de Materiales. ETSI Caminos, Canales y Puertos. Universidad Politécnica de Madrid. 28040. Madrid. Spain
| | - Manuel Elices
- Centro de Tecnología Biomédica. Universidad Politécnica de Madrid. 28223 Pozuelo de Alarcón (Madrid). Spain.,Departamento de Ciencia de Materiales. ETSI Caminos, Canales y Puertos. Universidad Politécnica de Madrid. 28040. Madrid. Spain
| | - José Pérez-Rigueiro
- Centro de Tecnología Biomédica. Universidad Politécnica de Madrid. 28223 Pozuelo de Alarcón (Madrid). Spain.,Departamento de Ciencia de Materiales. ETSI Caminos, Canales y Puertos. Universidad Politécnica de Madrid. 28040. Madrid. Spain
| |
Collapse
|
23
|
Cenis JL, Madurga R, Aznar-Cervantes SD, Lozano-Pérez AA, Marí-Buyé N, Meseguer-Olmo L, Plaza GR, Guinea GV, Elices M, Del Pozo F, Pérez-Rigueiro J. Mechanical behaviour and formation process of silkworm silk gut. Soft Matter 2015; 11:8981-8991. [PMID: 26403149 DOI: 10.1039/c5sm01877c] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
High performance silk fibers were produced directly from the silk glands of silkworms (Bombyx mori) following an alternative route to natural spinning. This route is based on a traditional procedure that consists of soaking the silk glands in a vinegar solution and stretching them by hand leading to the so called silkworm guts. Here we present, to the authors' best knowledge, the first comprehensive study on the formation, properties and microstructure of silkworm gut fibers. Comparison of the tensile properties and microstructural organization of the silkworm guts with those of naturally spun fibers allows gain of a deeper insight into the mechanisms that lead to the formation of the fiber, as well as the relationship between the microstructure and properties of these materials. In this regard, it is proved that an acidic environment and subsequent application of tensile stress in the range of 1000 kPa are sufficient conditions for the formation of a silk fiber.
Collapse
Affiliation(s)
- José L Cenis
- Instituto Murciano de Investigación y Desarrollo Agrario y Alimentario, 30150 La Alberca (Murcia), Spain
| | - Rodrigo Madurga
- Centro de Tecnología Biomédica, Universidad Politécnica de Madrid, 28223 Pozuelo de Alarcón (Madrid), Spain and Departamento de Ciencia de Materiales, ETSI Caminos, Canales y Puertos, Universidad Politécnica de Madrid, 28040, Madrid, Spain.
| | - Salvador D Aznar-Cervantes
- Instituto Murciano de Investigación y Desarrollo Agrario y Alimentario, 30150 La Alberca (Murcia), Spain
| | - A Abel Lozano-Pérez
- Instituto Murciano de Investigación y Desarrollo Agrario y Alimentario, 30150 La Alberca (Murcia), Spain
| | - Núria Marí-Buyé
- Centro de Tecnología Biomédica, Universidad Politécnica de Madrid, 28223 Pozuelo de Alarcón (Madrid), Spain and Departamento de Ciencia de Materiales, ETSI Caminos, Canales y Puertos, Universidad Politécnica de Madrid, 28040, Madrid, Spain.
| | - Luis Meseguer-Olmo
- Universidad Católica San Antonio de Murcia (UCAM) and Hospital Universitario "Virgen de la Arrixaca", 30120 El Palmar, Murcia, Spain
| | - Gustavo R Plaza
- Centro de Tecnología Biomédica, Universidad Politécnica de Madrid, 28223 Pozuelo de Alarcón (Madrid), Spain and Departamento de Ciencia de Materiales, ETSI Caminos, Canales y Puertos, Universidad Politécnica de Madrid, 28040, Madrid, Spain.
| | - Gustavo V Guinea
- Centro de Tecnología Biomédica, Universidad Politécnica de Madrid, 28223 Pozuelo de Alarcón (Madrid), Spain and Departamento de Ciencia de Materiales, ETSI Caminos, Canales y Puertos, Universidad Politécnica de Madrid, 28040, Madrid, Spain.
| | - Manuel Elices
- Centro de Tecnología Biomédica, Universidad Politécnica de Madrid, 28223 Pozuelo de Alarcón (Madrid), Spain and Departamento de Ciencia de Materiales, ETSI Caminos, Canales y Puertos, Universidad Politécnica de Madrid, 28040, Madrid, Spain.
| | - Francisco Del Pozo
- Centro de Tecnología Biomédica, Universidad Politécnica de Madrid, 28223 Pozuelo de Alarcón (Madrid), Spain
| | - José Pérez-Rigueiro
- Centro de Tecnología Biomédica, Universidad Politécnica de Madrid, 28223 Pozuelo de Alarcón (Madrid), Spain and Departamento de Ciencia de Materiales, ETSI Caminos, Canales y Puertos, Universidad Politécnica de Madrid, 28040, Madrid, Spain.
| |
Collapse
|
24
|
Jiang P, Marí-Buyé N, Madurga R, Arroyo-Hernández M, Solanas C, Gañán A, Daza R, Plaza GR, Guinea GV, Elices M, Cenis JL, Pérez-Rigueiro J. Spider silk gut: development and characterization of a novel strong spider silk fiber. Sci Rep 2014; 4:7326. [PMID: 25475975 PMCID: PMC4256644 DOI: 10.1038/srep07326] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2014] [Accepted: 11/19/2014] [Indexed: 11/09/2022] Open
Abstract
Spider silk fibers were produced through an alternative processing route that differs widely from natural spinning. The process follows a procedure traditionally used to obtain fibers directly from the glands of silkworms and requires exposure to an acid environment and subsequent stretching. The microstructure and mechanical behavior of the so-called spider silk gut fibers can be tailored to concur with those observed in naturally spun spider silk, except for effects related with the much larger cross-sectional area of the former. In particular spider silk gut has a proper ground state to which the material can revert independently from its previous loading history by supercontraction. A larger cross-sectional area implies that spider silk gut outperforms the natural material in terms of the loads that the fiber can sustain. This property suggests that it could substitute conventional spider silk fibers in some intended uses, such as sutures and scaffolds in tissue engineering.
Collapse
Affiliation(s)
- Ping Jiang
- College of Life Sciences, Jinggangshan University, Jiangxi Province, Ji'an. 343009, China
- Centro de Tecnología Biomédica. Universidad Politécnica de Madrid. 28223 Pozuelo de Alarcón (Madrid). Spain
| | - Núria Marí-Buyé
- Centro de Tecnología Biomédica. Universidad Politécnica de Madrid. 28223 Pozuelo de Alarcón (Madrid). Spain
- Departamento de Ciencia de Materiales. ETSI Caminos, Canales y Puertos. Universidad Politécnica de Madrid. 28040. Madrid. Spain
| | - Rodrigo Madurga
- Centro de Tecnología Biomédica. Universidad Politécnica de Madrid. 28223 Pozuelo de Alarcón (Madrid). Spain
- Departamento de Ciencia de Materiales. ETSI Caminos, Canales y Puertos. Universidad Politécnica de Madrid. 28040. Madrid. Spain
| | - María Arroyo-Hernández
- Centro de Tecnología Biomédica. Universidad Politécnica de Madrid. 28223 Pozuelo de Alarcón (Madrid). Spain
- Departamento de Ciencia de Materiales. ETSI Caminos, Canales y Puertos. Universidad Politécnica de Madrid. 28040. Madrid. Spain
| | - Concepción Solanas
- Centro de Tecnología Biomédica. Universidad Politécnica de Madrid. 28223 Pozuelo de Alarcón (Madrid). Spain
- Departamento de Ciencia de Materiales. ETSI Caminos, Canales y Puertos. Universidad Politécnica de Madrid. 28040. Madrid. Spain
| | - Alfonso Gañán
- Escuela Técnica Superior de Ingenieros. Universidad de Sevilla. 41092. Sevilla. Spain
| | - Rafael Daza
- Centro de Tecnología Biomédica. Universidad Politécnica de Madrid. 28223 Pozuelo de Alarcón (Madrid). Spain
- Departamento de Ciencia de Materiales. ETSI Caminos, Canales y Puertos. Universidad Politécnica de Madrid. 28040. Madrid. Spain
| | - Gustavo R. Plaza
- Centro de Tecnología Biomédica. Universidad Politécnica de Madrid. 28223 Pozuelo de Alarcón (Madrid). Spain
- Departamento de Ciencia de Materiales. ETSI Caminos, Canales y Puertos. Universidad Politécnica de Madrid. 28040. Madrid. Spain
| | - Gustavo V. Guinea
- Centro de Tecnología Biomédica. Universidad Politécnica de Madrid. 28223 Pozuelo de Alarcón (Madrid). Spain
- Departamento de Ciencia de Materiales. ETSI Caminos, Canales y Puertos. Universidad Politécnica de Madrid. 28040. Madrid. Spain
| | - Manuel Elices
- Centro de Tecnología Biomédica. Universidad Politécnica de Madrid. 28223 Pozuelo de Alarcón (Madrid). Spain
- Departamento de Ciencia de Materiales. ETSI Caminos, Canales y Puertos. Universidad Politécnica de Madrid. 28040. Madrid. Spain
| | - José Luis Cenis
- Instituto Murciano de Investigación y Desarrollo Agrario y Alimentario. 30150 La Alberca (Murcia). Spain
| | - José Pérez-Rigueiro
- Centro de Tecnología Biomédica. Universidad Politécnica de Madrid. 28223 Pozuelo de Alarcón (Madrid). Spain
- Departamento de Ciencia de Materiales. ETSI Caminos, Canales y Puertos. Universidad Politécnica de Madrid. 28040. Madrid. Spain
| |
Collapse
|
25
|
Perea GB, Riekel C, Guinea GV, Madurga R, Daza R, Burghammer M, Hayashi C, Elices M, Plaza GR, Pérez-Rigueiro J. Identification and dynamics of polyglycine II nanocrystals in Argiope trifasciata flagelliform silk. Sci Rep 2013; 3:3061. [PMID: 24162473 PMCID: PMC3808813 DOI: 10.1038/srep03061] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2013] [Accepted: 10/11/2013] [Indexed: 11/09/2022] Open
Abstract
Spider silks combine a significant number of desirable characteristics in one material, including large tensile strength and strain at breaking, biocompatibility, and the possibility of tailoring their properties. Major ampullate gland silk (MAS) is the most studied silk and their properties are explained by a double lattice of hydrogen bonds and elastomeric protein chains linked to polyalanine β-nanocrystals. However, many basic details regarding the relationship between composition, microstructure and properties in silks are still lacking. Here we show that this relationship can be traced in flagelliform silk (Flag) spun by Argiope trifasciata spiders after identifying a phase consisting of polyglycine II nanocrystals. The presence of this phase is consistent with the dominant presence of the -GGX- and -GPG- motifs in its sequence. In contrast to the passive role assigned to polyalanine nanocrystals in MAS, polyglycine II nanocrystals can undergo growing/collapse processes that contribute to increase toughness and justify the ability of Flag to supercontract.
Collapse
Affiliation(s)
- G. B. Perea
- Centro de Tecnología Biomédica. Universidad Politécnica de Madrid. 28223 Pozuelo de Alarcón (Madrid). Spain
- Departamento de Ciencia de Materiales. ETSI Caminos, Canales y Puertos. Universidad Politécnica de Madrid. 28040. Madrid. Spain
| | - C. Riekel
- European Synchroton Radiation Facility. B.P. 220, F-38043, Grenoble Cedex, France
| | - G. V. Guinea
- Centro de Tecnología Biomédica. Universidad Politécnica de Madrid. 28223 Pozuelo de Alarcón (Madrid). Spain
- Departamento de Ciencia de Materiales. ETSI Caminos, Canales y Puertos. Universidad Politécnica de Madrid. 28040. Madrid. Spain
| | - R. Madurga
- Centro de Tecnología Biomédica. Universidad Politécnica de Madrid. 28223 Pozuelo de Alarcón (Madrid). Spain
- Departamento de Ciencia de Materiales. ETSI Caminos, Canales y Puertos. Universidad Politécnica de Madrid. 28040. Madrid. Spain
| | - R. Daza
- Centro de Tecnología Biomédica. Universidad Politécnica de Madrid. 28223 Pozuelo de Alarcón (Madrid). Spain
- Departamento de Ciencia de Materiales. ETSI Caminos, Canales y Puertos. Universidad Politécnica de Madrid. 28040. Madrid. Spain
| | - M. Burghammer
- European Synchroton Radiation Facility. B.P. 220, F-38043, Grenoble Cedex, France
| | - C. Hayashi
- Department of Biology. University of California, Riverside. CA 92521. USA
| | - M. Elices
- Centro de Tecnología Biomédica. Universidad Politécnica de Madrid. 28223 Pozuelo de Alarcón (Madrid). Spain
- Departamento de Ciencia de Materiales. ETSI Caminos, Canales y Puertos. Universidad Politécnica de Madrid. 28040. Madrid. Spain
| | - G. R. Plaza
- Centro de Tecnología Biomédica. Universidad Politécnica de Madrid. 28223 Pozuelo de Alarcón (Madrid). Spain
- Departamento de Ciencia de Materiales. ETSI Caminos, Canales y Puertos. Universidad Politécnica de Madrid. 28040. Madrid. Spain
| | - J. Pérez-Rigueiro
- Centro de Tecnología Biomédica. Universidad Politécnica de Madrid. 28223 Pozuelo de Alarcón (Madrid). Spain
- Departamento de Ciencia de Materiales. ETSI Caminos, Canales y Puertos. Universidad Politécnica de Madrid. 28040. Madrid. Spain
| |
Collapse
|